Gainers
- NuCana NCNA stock rose 17.3% to $0.84 during Friday's after-market session. This security traded at a volume of 164.1K shares come close, making up 395.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $44.0 million.
- Neuronetics STIM stock rose 10.22% to $1.94. The market value of their outstanding shares is at $56.0 million. As per the press release, Q2 earnings came out 3 days ago.
- AIM ImmunoTech AIM stock rose 9.49% to $0.64. The company's market cap stands at $30.9 million.
- Baudax Bio BXRX shares moved upwards by 8.38% to $0.63. The market value of their outstanding shares is at $4.5 million.
- Nemaura Medical NMRD stock increased by 8.1% to $0.88. The market value of their outstanding shares is at $25.4 million.
- Virax Biolabs Group VRAX shares rose 8.1% to $0.4. The market value of their outstanding shares is at $7.1 million.
Losers
- PHAXIAM Therapeutics PHXM stock declined by 8.9% to $0.51 during Friday's after-market session. At the close, PHAXIAM Therapeutics's trading volume reached 67.5K shares. This is 30.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $31.1 million.
- Synlogic SYBX stock decreased by 8.3% to $0.49. The company's market cap stands at $33.0 million. As per the press release, Q2 earnings came out yesterday.
- Aveanna Healthcare Hldgs AVAH stock decreased by 8.16% to $1.69. The company's market cap stands at $314.1 million. The company's, Q2 earnings came out yesterday.
- Syros Pharmaceuticals SYRS shares decreased by 8.12% to $3.51. The market value of their outstanding shares is at $72.6 million. As per the press release, Q2 earnings came out 3 days ago.
- China Pharma Holding CPHI shares fell 7.21% to $0.23. The company's market cap stands at $2.2 million.
- SAB Biotherapeutics SABS stock fell 5.43% to $0.76. The market value of their outstanding shares is at $39.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in